PR Newswire

The newsfeed available here is provided by our content partner PR Newswire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 72.244 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
PR Newswire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US7751331015
State: 17.08.2024 | 11PM
Do you already know our new terminal view? Click here.
FIGI: BBG000BQF8S5
ROG
Rogers Corporation
GICS: 45203015 · Sector: Technology · Sub-Sector: Hardware, Equipment & Parts
NAME
Rogers Corporation
ISIN
US7751331015
TICKER
ROG
MIC
XNYS
REUTERS
ROG.N
BLOOMBERG
ROG US
Mon, 13.01.2025       Rogers
US7751331015

The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2 The test helps differentiate a B-cell cancer from a normal, reactive immune response, offering diagnostic certainty for healthcare providers and their patients. B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL) cases, which is one of the most common cancers in the US.3
Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Rogers
US7751331015

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers.The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.

TUCSON, Ariz., Nov. 18, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first immunohistochemistry (IHC) companion diagnostic test to be made widely available in Europe to aid in identifying epithelial ovarian cancer (EOC) patients who may be eligible for targeted treatment with ELAHERE® (mirvetuximab soravtansine). ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy developed by AbbVie for the treatment of FRɑ-positive platinum-resistant ovarian cancer.

Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Rogers
US7751331015

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers.The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.

TUCSON, Ariz., Nov. 18, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first immunohistochemistry (IHC) companion diagnostic test to be made widely available in Europe to aid in identifying epithelial ovarian cancer (EOC) patients who may be eligible for targeted treatment with ELAHERE® (mirvetuximab soravtansine). ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy developed by AbbVie for the treatment of FRɑ-positive platinum-resistant ovarian cancer.

Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink
Fri, 18.10.2024       Rogers
US7751331015

The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may benefit from a targeted treatment option. CLDN18.2 is an emerging biomarker in gastric and GEJ cancers and helps predict the likelihood of response to targeted therapy.As the leader in companion diagnostics, Roche continues to build on its commitment to improve personalised healthcare to enable better patient outcomes.
Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Rogers
US7751331015

Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with nearly one-third being unsure or unaware of it altogether.1Findings also show that significant barriers continue to exist that are preventing women from seeking screening.1However, more than 70% of the respondents indicated they would be interested in the option of collecting their own sample for screening if available.

TUCSON, Ariz., Oct. 8, 2024 /PRNewswire/ -- GWI research commissioned by Roche (SIX: RO, ROG; OTCQX: RHHBY) and carried out across 12 countries in Latin America and Europe has revealed that half of those polled have either limited or no awareness of the important role human papillomavirus (HPV) plays in cervical cancer.1

Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Rogers
US7751331015

Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with nearly one-third being unsure or unaware of it altogether.1Findings also show that significant barriers continue to exist that are preventing women from seeking screening.1However, more than 70% of the respondents indicated they would be interested in the option of collecting their own sample for screening if available.

TUCSON, Ariz., Oct. 8, 2024 /PRNewswire/ -- GWI research commissioned by Roche (SIX: RO, ROG; OTCQX: RHHBY) and carried out across 12 countries in Latin America and Europe has revealed that half of those polled have either limited or no awareness of the important role human papillomavirus (HPV) plays in cervical cancer.1

Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink
Thu, 25.07.2024       Rogers
US7751331015

Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry.Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab operations, optimize resources and expedite care.The Roche exhibit booth and Roche Idea Lab series featuring industry experts will highlight how elevating diagnostics can lead to more insights and better patient outcomes.

INDIANAPOLIS and CHICAGO, July 25, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a laboratory of the future exhibit at the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo, July 28 through August 1 in Chicago. Attendees will have the opportunity to experience how Roche's growing portfolio of integrated systems and data solutions optimizes resources and simplifies and streamlines operations while driving better health outcomes.

Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink
Tue, 30.01.2024       Rogers
US7751331015

LONDON, 30. Januar 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY), eines der weltweit größten Pharmaunternehmen, wurde mit der IDC-Auszeichnung Future Enterprise Best in Future of Intelligence EMEA für seine Enterprise Self-Service-Datenplattform ausgezeichnet, die Immuta® für den Datenschutz und die fein abgestufte Zugriffskontrolle sowohl auf zentraler als auch auf Domänenebene nutzt. IDC ist ein weltweit führender Anbieter von Marktinformationen und Beratungsdiensten. Mit der Auszeichnung werden Unternehmen gewürdigt, die in den Bereichen Innovation, digitale Transformation und betriebliche Exzellenz führend sind. Im ersten Jahr seines Bestehens wurden für das Programm Bewerbungen aus über 15 Branchen und von über 600 Unternehmen eingereicht.

Read More
Rogers
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.